BioSpace News Archive

STERIS plc announced that it will host a conference call to discuss its fiscal 2022 fourth quarter and full year financial results at 10:00 a.m. ET on May 12, 2022.

Accelerate Diagnostics, Inc. today announced the release of new data on the Accelerate Arc Module and BC kit at the 32nd European Congress for Clinical Microbiology and Infectious Diseases (ECCMID) located in Lisbon, Portugal 23-26 April 2022.

Progenity, Inc., a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, announced the appointment of Paul Shabram, MBA, as Senior Vice President, Technical Operations.

Cassava Sciences, Inc. announced that it has been invited to participate in the B. Riley Securities’ Neuroscience Conference, a virtual event taking place on April 27-28, 2022.

Black Diamond Therapeutics, Inc. today announced that it is realigning its resources to focus on key near-term value drivers and to extend its cash runway into the third quarter of 2024, supporting the execution of important clinical and preclinical milestones.

Abbott (NYSE: ABT) today announced that it has launched an upgraded version of its NeuroSphere™ myPath™ digital health app with enhanced functionality that will help doctors more closely track their patients as they trial Abbott neurostimulation devices to address their chronic pain.

TeDan Surgical Innovations announced the launch of the single-use, sterile Phantom Multi-Bite™ Kerrison Rongeur and Phantom Bone Collector for laminectomy, decompression, or other spinal procedures requiring bone removal and harvesting.

Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today announced the formation of a Scientific Advisory Board (“SAB”) for its INBRX-101 program for the treatment of alpha-1 antitrypsin deficiency (“AATD”).

CoNextions® Inc. (www.conextionsmed.com), an innovator in tendon repair, is pleased to announce that CoNextions TR® Tendon Repair System has received FDA 510(k) Clearance.

BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTCQB:BVAXF) (“BioVaxys” or “Company”), announced today that it has entered into an agreement with the Deaconess Research Institute (“DRI”) to supply BioVaxys with surgically debulked tumors from Stage III/Stage IV ovarian cancer patients undergoing treatment at Deaconess Health System (“Deaconess”).